Theravance Biopharma, Inc. Announces Top-line Results from a Pha
44
TBPH: Theravance Biopharma, Inc. 2021-09-15 06:05:00 Theravance Biopharma, Inc. Announces Top-line Results from a Phase 3 Study of Ampreloxetine in Patients with Symptomatic Neurogenic Orthostatic Hypotension